CRISPR Therapeutics

Company Overview

CRISPR Therapeutics is a gene editing company that develops CRISPR/Cas9-based therapies. It utilizes CRISPR to disrupt, delete, correct, and insert genes, thereby treating genetic diseases and engineering advanced cellular therapies. Its therapeutic portfolio spans four core franchises. In hemoglobinopathies, Casgevy is approved for the treatment of severe sickle cell disease and transfusion-dependent beta-thalassemia, with ongoing research in stem cell editing. In immuno-oncology and autoimmune disorders, gene-edited CAR T cell therapies are advancing. It also targets common and rare diseases through in vivo approaches, starting with CVD, and is developing stem cell therapies for type 1 diabetes that eliminate the need for chronic immunosuppression.

CRISPR Therapeutics has a presence in Switzerland and the U.S., with its U.S. subsidiary, CRISPR Therapeutics Inc. Additionally, it has research and development operations in Boston and San Francisco, as well as business offices in London.

Financial Highlights (FY 2025)

Company's Business Segments

• Gene Editing : CRISPR therapeutics